We are live on ! Find out more
EDIT icon

Editas Medicine

236 hedge funds and large institutions have $384M invested in Editas Medicine in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 60 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $5.68M | Put options by funds: $4.54M

15% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 60

2.6% less ownership

Funds ownership: 78.6% → 76% (-2.6%)

6% less funds holding

Funds holding: 251 → 236 (-15)

22% less capital inflows, than outflows

Capital inflows: $50.9M | Capital outflows: $65.3M

32% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 41

Holders
236
Holders Change
-15
Holders Change %
-5.98%
% of All Funds
3.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
69
Reduced
60
Closed
41
Calls
$5.68​M
Puts
$4.54​M
Net Calls
+$1.14​M
Net Calls Change
-⁠$3.76​M

EDIT Hedge Fund Activity: Q1 2023 in Review

236 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2023, worth a combined $384M — down 20% from $479M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of EDIT and 28 opened new positions — a net loss of 13 holders — while 60 trimmed existing stakes and 69 added.

The largest buyer was Pictet Asset Management, adding an estimated $7.19M. The largest seller was Capital World Investors, exiting entirely with an estimated $9.8M sold.

  • 236 institutional investors held Editas Medicine (EDIT) as of Q1 2023, down from 251 in Q4 2022.
  • Funds reported $384M of Editas Medicine stock for Q1 2023, down 20% quarter-over-quarter.
  • 28 funds opened new Editas Medicine positions in Q1 2023 and 41 closed out, a net change of -13 holders.
  • The largest Editas Medicine buyer in Q1 2023 was Pictet Asset Management, an estimated $7.19M added.
  • The largest Editas Medicine seller in Q1 2023 was Capital World Investors, an estimated $9.8M sold.

Based on aggregated 13F filings for Q1 2023.